CC-312

N/A

Report date: 2026/03/19 17:18:22

Base Information

Drug NameCC-312
Drug Alias NameCC-312
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD19CD3 T-cell engagersT-cell-specific surface glycoprotein CD28 agonists
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPurpura, Thrombocytopenic, Idiopathic +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCytoCares (Shanghai) Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCytoCares (Shanghai) Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPurpura, Thrombocytopenic, Idiopathic +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A